FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3139293810> ?p ?o ?g. }

• W3139293810 endingPage "410" @default.
• W3139293810 startingPage "410" @default.
• W3139293810 abstract "Triple-negative breast cancer (TNBC) is a malignant subtype of breast cancer, the main treatments for which are chemotherapy and surgery. PIK3CA is an oncogene that encodes the p110α subunit of class IA PI3K to regulate cell proliferation and apoptosis. Some reports have observed neoadjuvant chemotherapy (NAC) to have poor pathological complete response (pCR) rates in TNBC with PIK3CA mutation. This study aimed to explore the mechanism of how mutant PIK3CA alters chemotherapeutic susceptibility in TNBC.TNBC cell lines (MDA-MB-231 and MDA-MB-468) with PIK3CA gene mutations (E545K and H1047R regions) and overexpression were established by transfection. NOD/SCID mice were used for in vivo experiments. Epirubicin was used as the chemotherapeutic agent. Cell viability, cell cycle, apoptosis, and Transwell assays were conducted for phenotype analysis. Western blot, quantitative reverse transcription-polymerase chain reaction, and immunohistochemistry were used to detect gene and protein expression levels. A clinical analysis of 50 patients with TNBC was also performed.Cell viability and Transwell assays showed that PIK3CA mutation promoted TNBC cell growth and conferred an enhanced migratory phenotype. Cell cycle and apoptosis assays showed that PIK3CA mutation moderately improved the proliferation ability of TNBC cells and remarkably inhibited their apoptosis. After epirubicin therapy, the proportion of early apoptotic cells decreased among cells with PIK3CA mutation. Further, xenograft tumors grew faster in NOD/SCID mice injected with mutated cell lines than in control group, suggesting that PIK3CA mutation caused chemotherapy resistance. Importantly, western blot and immunohistochemical analysis showed that cells and mouse tumors in the PIK3CA mutation groups exhibited different expression levels of apoptosis-related markers (Xiap, Bcl-2, and Caspase 3) and proteins associated with the PI3K/AKT/mTOR pathway (p110α, AKT, p-AKT, mTOR, p-mTOR, p-4E-BP1, p-p70S6K, and Pten). Moreover, prognostic analysis of 50 patients with TNBC indicated that PIK3CA mutation might be linked with relapse and death.PIK3CA mutation confers resistance to chemotherapy in TNBC by inhibiting apoptosis and activating the PI3K/AKT/mTOR signaling pathway." @default.
• W3139293810 created "2021-03-29" @default.
• W3139293810 creator A5012258010 @default.
• W3139293810 creator A5015997947 @default.
• W3139293810 creator A5022537607 @default.
• W3139293810 creator A5025798796 @default.
• W3139293810 creator A5036278731 @default.
• W3139293810 creator A5037255490 @default.
• W3139293810 creator A5038262998 @default.
• W3139293810 creator A5043560261 @default.
• W3139293810 creator A5061253679 @default.
• W3139293810 creator A5077393747 @default.
• W3139293810 creator A5079978233 @default.
• W3139293810 creator A5082365446 @default.
• W3139293810 date "2021-03-01" @default.
• W3139293810 modified "2023-10-16" @default.
• W3139293810 title "PIK3CA mutation confers resistance to chemotherapy in triple-negative breast cancer by inhibiting apoptosis and activating the PI3K/AKT/mTOR signaling pathway" @default.
• W3139293810 cites W1856378891 @default.
• W3139293810 cites W1964272015 @default.
• W3139293810 cites W1971843650 @default.
• W3139293810 cites W2000954296 @default.
• W3139293810 cites W2019607817 @default.
• W3139293810 cites W2024796296 @default.
• W3139293810 cites W2030899725 @default.
• W3139293810 cites W2054607545 @default.
• W3139293810 cites W2078358665 @default.
• W3139293810 cites W2084016080 @default.
• W3139293810 cites W2085483616 @default.
• W3139293810 cites W2088190208 @default.
• W3139293810 cites W2096027508 @default.
• W3139293810 cites W2134539328 @default.
• W3139293810 cites W2152654745 @default.
• W3139293810 cites W2154608911 @default.
• W3139293810 cites W2161062799 @default.
• W3139293810 cites W2166872093 @default.
• W3139293810 cites W2209515009 @default.
• W3139293810 cites W2546933714 @default.
• W3139293810 cites W2560367415 @default.
• W3139293810 cites W2729967392 @default.
• W3139293810 cites W2767814595 @default.
• W3139293810 cites W2889646458 @default.
• W3139293810 cites W2916258951 @default.
• W3139293810 cites W2921768356 @default.
• W3139293810 cites W2943363006 @default.
• W3139293810 cites W2945564879 @default.
• W3139293810 cites W2969263349 @default.
• W3139293810 cites W2985804592 @default.
• W3139293810 cites W2989217850 @default.
• W3139293810 cites W2995209087 @default.
• W3139293810 cites W3002154893 @default.
• W3139293810 cites W3004647644 @default.
• W3139293810 cites W3004753443 @default.
• W3139293810 cites W3021746852 @default.
• W3139293810 cites W3025589456 @default.
• W3139293810 cites W3028525915 @default.
• W3139293810 cites W3042003749 @default.
• W3139293810 cites W3080313180 @default.
• W3139293810 cites W3083487657 @default.
• W3139293810 cites W3093593152 @default.
• W3139293810 cites W3104936322 @default.
• W3139293810 cites W3113405673 @default.
• W3139293810 doi "https://doi.org/10.21037/atm-21-698" @default.
• W3139293810 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8033310" @default.
• W3139293810 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33842631" @default.
• W3139293810 hasPublicationYear "2021" @default.
• W3139293810 type Work @default.
• W3139293810 sameAs 3139293810 @default.
• W3139293810 citedByCount "30" @default.
• W3139293810 countsByYear W31392938102021 @default.
• W3139293810 countsByYear W31392938102022 @default.
• W3139293810 countsByYear W31392938102023 @default.
• W3139293810 crossrefType "journal-article" @default.
• W3139293810 hasAuthorship W3139293810A5012258010 @default.
• W3139293810 hasAuthorship W3139293810A5015997947 @default.
• W3139293810 hasAuthorship W3139293810A5022537607 @default.
• W3139293810 hasAuthorship W3139293810A5025798796 @default.
• W3139293810 hasAuthorship W3139293810A5036278731 @default.
• W3139293810 hasAuthorship W3139293810A5037255490 @default.
• W3139293810 hasAuthorship W3139293810A5038262998 @default.
• W3139293810 hasAuthorship W3139293810A5043560261 @default.
• W3139293810 hasAuthorship W3139293810A5061253679 @default.
• W3139293810 hasAuthorship W3139293810A5077393747 @default.
• W3139293810 hasAuthorship W3139293810A5079978233 @default.
• W3139293810 hasAuthorship W3139293810A5082365446 @default.
• W3139293810 hasBestOaLocation W31392938101 @default.
• W3139293810 hasConcept C121608353 @default.
• W3139293810 hasConcept C153911025 @default.
• W3139293810 hasConcept C190283241 @default.
• W3139293810 hasConcept C2780110267 @default.
• W3139293810 hasConcept C2780835546 @default.
• W3139293810 hasConcept C502942594 @default.
• W3139293810 hasConcept C530470458 @default.
• W3139293810 hasConcept C53227056 @default.
• W3139293810 hasConcept C54355233 @default.
• W3139293810 hasConcept C62112901 @default.
• W3139293810 hasConcept C86554907 @default.
• W3139293810 hasConcept C86803240 @default.
• W3139293810 hasConceptScore W3139293810C121608353 @default.

• next